MY105308A - Imadazo[4,5-b]quinoloxyalkanoic acid amides with enhanced water solubility. - Google Patents

Imadazo[4,5-b]quinoloxyalkanoic acid amides with enhanced water solubility.

Info

Publication number
MY105308A
MY105308A MYPI90001900A MYPI19901900A MY105308A MY 105308 A MY105308 A MY 105308A MY PI90001900 A MYPI90001900 A MY PI90001900A MY PI19901900 A MYPI19901900 A MY PI19901900A MY 105308 A MY105308 A MY 105308A
Authority
MY
Malaysia
Prior art keywords
carbon atoms
alkyl
cycloalkyl
acid amides
water solubility
Prior art date
Application number
MYPI90001900A
Inventor
Meanwell Nicholas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MY105308A publication Critical patent/MY105308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A NOVEL SERIES OF 2, 3-DIHYDRO-2-OXO-1H-IMIDAZO- [4, 5-B] QUINOLINYLOXYALKANOIC ACID AMIDES HAVING ENHANCED WATER SOLUBILITY IS DISCLOSED OF THE FORMULA WHEREIN N IS 3 TO 5; R1 IS ALKYL OF 1 TO 4 CARBON ATOMS; R2 IS HYDROGEN; R3 IS 1-PIPERIDINYLETHYL, 1-BENZYLPIPERIDIN-4-YL, 4-(1-PIPERIDINYL) PIPERIDINE, (1-ALKYL-2-PYRROLIDINYL) -ALKYL WHERE ALKYL IS 1 TO 4 CARBON ATOMS, 3-QUINUCLIDINYL; R2 AND R3 TOGETHER WITH THE NITROGEN ATOM TO WHICH THEY ARE ATTACHED FORM 4-R4-PIPERAZIN-1-YL WHEREIN R4 IS ALKYL OF 1 TO 7 CARBON ATOMS, ALKOXYETHYL OF 3 TO 7 CARBON ATOMS, PYRIDINYL, PYRIMIDINYL, TETRAHYDROPYRANYLMETHYL, THIENYLMETHYL, CYCLOALKYL- (CH2)M WHERE M IS ZERO OR ONE AND CYCLOALKYL IS 5 TO 7 CARBON ATOMS EXCEPT M IS ZERO WHEN CYCLOALKYL IS 7 CARBON ATOMS, BENZYL, 4-FLUOROBENZYL, 3-TRIFLUOROMETHYLBENZYL, 4-ALKOXYBENZYL WHERE ALKOXY IS 1 TO 4 CARBON ATOMS. THE COMPOUNDS ARE CYCLIC AMP PHOSPHODIESTERASE INHIBITORS AND ARE PARTICULARLY USEFUL AS INHIBITORS OF BLOOD PLATELET AGGREGATION AND/OR AS CARDIOTONIC AGENTS.
MYPI90001900A 1989-11-01 1990-10-30 Imadazo[4,5-b]quinoloxyalkanoic acid amides with enhanced water solubility. MY105308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/430,228 US4943573A (en) 1989-11-01 1989-11-01 Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Publications (1)

Publication Number Publication Date
MY105308A true MY105308A (en) 1994-09-30

Family

ID=23706624

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001900A MY105308A (en) 1989-11-01 1990-10-30 Imadazo[4,5-b]quinoloxyalkanoic acid amides with enhanced water solubility.

Country Status (20)

Country Link
US (1) US4943573A (en)
EP (1) EP0426180A3 (en)
JP (1) JPH03169880A (en)
KR (1) KR910009705A (en)
CN (1) CN1025999C (en)
AU (1) AU639033B2 (en)
CA (1) CA2027935A1 (en)
EG (1) EG19372A (en)
FI (1) FI92697C (en)
HU (1) HU209305B (en)
IE (1) IE61579B1 (en)
IL (1) IL96167A (en)
MY (1) MY105308A (en)
NO (1) NO175531C (en)
NZ (1) NZ235868A (en)
OA (1) OA09323A (en)
PT (1) PT95765A (en)
RU (1) RU2041210C1 (en)
YU (1) YU205590A (en)
ZA (1) ZA908725B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
TW593317B (en) * 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996005202A1 (en) * 1994-08-17 1996-02-22 Nippon Hypox Laboratories Inc. Imidazoquinoline derivative
US5798767A (en) * 1996-03-15 1998-08-25 Rendition, Inc. Method and apparatus for performing color space conversion using blend logic
SE9902987D0 (en) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (en) 2006-05-09 2009-03-25 Braincells Inc 5 ht receptor mediated neurogenesis.
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
WO2008016669A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
JP2010502722A (en) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド Combinations containing 4-acylaminopyridine derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2139478A4 (en) * 2007-03-30 2010-05-05 Cytokinetics Inc Certain chemical entities, compositions and methods
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (en) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. METHOD FOR OBTAINING GUANYLATZCLAZE AGONISTS C
SG10201605707UA (en) 2011-07-13 2016-09-29 Cytokinetics Inc Combination als therapy
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN114340631A (en) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 Combination for reducing serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (en) * 1977-07-25 1979-01-29 Hoffmann La Roche TRICYCLICAL CONNECTIONS.
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
JPS60193991A (en) * 1984-02-15 1985-10-02 シンテツクス（ユー・エス・エイ）インコーポレイテツド Imidazoquinazolinyloxyalkylamide derivative
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Also Published As

Publication number Publication date
JPH03169880A (en) 1991-07-23
NO904689L (en) 1991-05-02
RU2041210C1 (en) 1995-08-09
US4943573A (en) 1990-07-24
NO904689D0 (en) 1990-10-30
HU209305B (en) 1994-04-28
OA09323A (en) 1992-09-15
HU906977D0 (en) 1991-05-28
EP0426180A2 (en) 1991-05-08
PT95765A (en) 1991-09-13
ZA908725B (en) 1991-07-31
IL96167A0 (en) 1991-07-18
FI905326A0 (en) 1990-10-29
KR910009705A (en) 1991-06-28
FI92697B (en) 1994-09-15
EG19372A (en) 1994-12-30
CN1025999C (en) 1994-09-28
CN1051359A (en) 1991-05-15
EP0426180A3 (en) 1992-01-08
AU6567990A (en) 1991-05-23
NO175531C (en) 1994-10-26
YU205590A (en) 1992-09-07
IL96167A (en) 1994-11-11
IE903923A1 (en) 1991-05-08
HUT56102A (en) 1991-07-29
CA2027935A1 (en) 1991-05-02
FI92697C (en) 1994-12-27
AU639033B2 (en) 1993-07-15
IE61579B1 (en) 1994-11-16
NZ235868A (en) 1993-12-23
NO175531B (en) 1994-07-18

Similar Documents

Publication Publication Date Title
MY105308A (en) Imadazo[4,5-b]quinoloxyalkanoic acid amides with enhanced water solubility.
DE69033100D1 (en) Piperazine derivatives
HUP0302943A2 (en) New heterocyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
HUP0301330A2 (en) 2-aminocarbonyl-9h-purine derivatives
DK1473294T3 (en) Substituted 1,3-oxathiolanes with antiviral properties
NO954453L (en) New pyridine, pyrimidine and benzene derivatives as adrenoceptor antagonists
ATE162527T1 (en) PIPERAZINE DERIVATIVES AS 5-HT1A ANTAGONISTS.
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
NO911158L (en) Hydantoin derivatives.
ATE102482T1 (en) USE OF 1,4-DISUBSTITUTED PIPERIDINYL COMPOUNDS IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF INSOMNIA.
TW330147B (en) Halogenobenzimidazoles, their preparation processes and their use
AU1120688A (en) - 8-heterocyclo-ergoline derivatives useful in the treatment of extrapyramidal syndromes
MX9303976A (en) DERIVATIVES OF 2-AMINO-N - {{((4- (AMINO CARBONYL) -PIRIMIDIN-2-IL-AMINO) -ALKYL} -PIRIMIDI N-4-CARBOXAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
ATE115572T1 (en) N-2-CHLOROBENZYL-2-OXO- AND N-2-CHLOROBENZYL-2,2,- DIOXO-1,2,3-OXATHIAZOLIDES, THEIR PREPARATION AND USE IN THE SYNTHESIS OF THIENO(3,2-C>PYRIDINE DERIVATIVES .
DK0658555T3 (en) Pyridazinone derivatives, processes for their preparation and their use
PH15866A (en) Substituted 4-amino 2,6-diaryl-tetrahydrothiopyrans and salts thereof,and use as antidepressants
TH13948A (en)
DK210387A (en) HETEROCYCLIC RELATIONS AND PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THESE
JPS6463569A (en) Heteroaryl derivative
DE3877361T2 (en) AMINE SALTS OF ALKAN-1, N-DICARBONIC ACID MONO- (2-SULFATO-AETHYL) AMIDES.
TH13243EX (en) Thiazolinone and oxasolidinone derivatives and their preparations and their use as vasodilators.
ATE91487T1 (en) DIBENZODIOXAZECIN AND DIBENZODIOXAAZACYCLOUNDECIN DERIVATIVES.